Procyon Advisors LLC Has $2.71 Million Holdings in Haleon plc (NYSE:HLN)

Procyon Advisors LLC lifted its position in Haleon plc (NYSE:HLN - Free Report) by 14.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 262,830 shares of the company's stock after buying an additional 32,590 shares during the quarter. Procyon Advisors LLC's holdings in Haleon were worth $2,705,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Sierra Ocean LLC bought a new position in Haleon during the fourth quarter worth $26,000. FIL Ltd increased its position in Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after acquiring an additional 1,270 shares during the period. Spire Wealth Management bought a new position in Haleon during the fourth quarter worth $39,000. Addison Advisors LLC raised its stake in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after buying an additional 1,106 shares in the last quarter. Finally, Mather Group LLC. raised its stake in shares of Haleon by 177.4% in the 4th quarter. Mather Group LLC. now owns 5,623 shares of the company's stock valued at $54,000 after buying an additional 3,596 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Price Performance

NYSE:HLN traded down $0.05 during mid-day trading on Friday, reaching $11.07. 13,897,070 shares of the company were exchanged, compared to its average volume of 8,750,126. Haleon plc has a 12 month low of $8.25 and a 12 month high of $11.42. The company has a fifty day moving average of $10.50 and a 200 day moving average of $10.03. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market cap of $49.84 billion, a PE ratio of 32.56, a PEG ratio of 2.82 and a beta of 0.31.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a report on Friday, May 9th. Wall Street Zen raised shares of Haleon from a "hold" rating to a "buy" rating in a report on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a report on Tuesday, May 27th. Finally, Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Haleon currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.